Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that it repurchased 264,000 H shares on 1 September 2026 via on-market transactions on the Hong Kong Stock Exchange.

Key transaction details • Volume: 264,000 H shares, equivalent to 0.05 % of the company’s issued H-share capital before the transaction. • Price range: HKD 16.07–16.28 per share, with a volume-weighted average cost of HKD 16.21. • Cash outflow: HKD 4.28 million. • Shares acquired were retained as treasury shares; none were cancelled as at the reporting date.

Share capital movement • Issued shares outstanding (excluding treasury shares) decreased from 540.68 million to 540.42 million. • Treasury share balance rose from 11.26 million to 11.52 million, leaving total issued shares unchanged at 551.94 million.

Mandate utilisation • The repurchase falls under the mandate approved on 16 June 2026, which authorises buybacks of up to 54.10 million shares. • Cumulative repurchases under this mandate now total 551,500 shares, representing approximately 0.10 % of the company’s issued shares on the mandate date. • In line with Hong Kong listing rules, Fosun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.

The company confirmed that all buybacks complied with Main Board Rule 10.06 and that no material changes have been made to the repurchase mandate’s explanatory statement.